09:08 AM EDT, 06/06/2024 (MT Newswires) -- Halozyme Therapeutics ( HALO ) said Thursday it is raising its 2024 guidance after receiving a European patent for its Enhanze drug delivery technology.

The company said it now expects 2024 non-GAAP earnings of $3.65 to $4.05 per diluted share, up from its prior guidance of $3.55 to $3.90.

Analysts polled by Capital IQ expect $3.70.

Revenue for the year is now expected to be $935 million to $1.02 billion, compared with its earlier expectation of between $915 million and $985 million.

Analysts surveyed by Capital IQ expect $959 million.

Shares of the company were up more than 4% in recent Thursday premarket activity.

Price: 47.67, Change: +2.02, Percent Change: +4.42